Table 1.
Characteristics of the patients.
Fig 1.
Incidence of tumor enhancement at baseline and during follow-up.
Fig 2.
Incidence of T2-weighted hyperintensity at baseline and during follow-up.
Fig 3.
Incidence of diffusion-weighted hyperintensity at baseline and during follow-up.
Fig 4.
MRI at three months. 4A Enhanced post-treatment changes on arterial phase. 4B. Enhanced post-treatment changes on venal phase. 4C. T2-weighted hyperintense post-treatment changes.
Fig 5.
5A. Sub-capsular HCC on arterial phase on dynamic 3D T1 weighted imaging at the time of diagnosis. 5B. MRI at six months: portal phase on dynamic 3D T1 weighted imaging. Post-treatment changes with hypervascular ring and capsular retraction.
Table 2.
Cox regression analyses of capsular retraction according to sub-capsular location of the tumor.
Fig 6.
Occurrence of a complete response according to RECIST and mRECIST.
Table 3.
Cox regression analyses of predictive factors at baseline and during follow-up of complete responses according to RECIST and mRECIST.
Fig 7.
7A.Segment VIII HCC on arterial phase on dynamic 3D T1 weighted imaging at the time of diagnosis. 7B. Tumor regression at three months after treatment on arterial phase on dynamic 3D T1 weighted imaging. Target-like image with tumor annular enhancement and peritumoral ring-like enhanced post-treatment changes. 7C. Complete regression of the tumor at six months after SBRT on arterial phase on dynamic 3D T1 weighted imaging with persistent enhanced post-treatment changes.